Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer

被引：0
|
作者：
Paul F. Schellhammer
Robert M. Hershberg
机构：
[1] Norfolk,Eastern Virginia Medical School and Devine Tidewater Urology
[2] Seattle,Dendreon Corporation
[3] 6333 Center Drive,Interstate Corporate Center
来源：
World Journal of Urology | 2005年 / 23卷
关键词：
Prostate cancer; Immunotherapy; Vaccine; Androgen independent; Provenge; Hormone refractory;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Prostate cancer is an excellent target for an active vaccine-based approach based on the fact that prostate cancer cells express unique proteins which serve as highly specific targets. APC8015 (Provenge) is one such investigational therapeutic vaccine that uses autologous antigen presenting cells (APCs) loaded with a recombinant fusion protein of prostatic acid phosphatase linked to a molecule that specifically targets a receptor expressed on the surface of human APCs. Clinical trial outcomes have demonstrated activity in patients with androgen independent prostate cancer.
引用
收藏
页码：47 / 49
页数：2
相关论文
共 50 条
  • [1] Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer
    Schellhammer, PF
    Hershberg, RM
    WORLD JOURNAL OF UROLOGY, 2005, 23 (01) : 47 - 49
  • [2] Androgen deprivation and immunotherapy for the treatment of prostate cancer
    Gamat, Melissa
    McNeel, Douglas G.
    ENDOCRINE-RELATED CANCER, 2017, 24 (12) : T297 - T310
  • [3] Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells
    Lin, Amy M.
    Hershberg, Robert M.
    Small, Eric J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2006, 24 (05) : 434 - 441
  • [4] Nanoscale artificial antigen presenting cells for cancer immunotherapy
    Rhodes, Kelly R.
    Green, Jordan J.
    MOLECULAR IMMUNOLOGY, 2018, 98 : 13 - 18
  • [5] Neoadjuvant immunotherapy for prostate cancer with GM-CSF and tumor infiltration by antigen presenting cells
    Fong, L.
    Dao, V.
    O'Brien, S.
    Simko, J.
    Weinberg, V. K.
    Ryan, C.
    Rosenberg, J. E.
    Lin, A. M.
    Carroll, P.
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Profiling of microRNAs in androgen independent prostate cancer cells
    Sharad, Shashwat
    Li, Hua
    CANCER RESEARCH, 2023, 83 (07)
  • [7] Treatment options in androgen-independent prostate cancer
    Lara, PN
    Meyers, FJ
    CANCER INVESTIGATION, 1999, 17 (02) : 137 - 144
  • [8] Elevated carcinoembryonic antigen in patients with androgen-independent prostate cancer
    Feuer, JA
    Lush, RM
    Venzon, D
    Duray, P
    Tompkins, A
    Sartor, O
    Figg, WD
    JOURNAL OF INVESTIGATIVE MEDICINE, 1998, 46 (02) : 66 - 72
  • [9] Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells:: APC8015 (Provenge®)
    Harzstark, Andrea L.
    Small, Eric J.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (08) : 1275 - 1280
  • [10] AZACITIDINE TREATMENT SENSITIZES AGAINST BICALUTAMIDE AND RADIOTHERAPY IN ANDROGEN INDEPENDENT PROSTATE CANCER CELLS
    Gravina, Giovanni Luca
    Festuccia, Claudio
    Di Sante, Stefania
    Marampon, Francesco
    Fratticci, Amato
    Carosa, Eleonora
    Castri, Alessandra
    Ventura, Luca
    Jannini, Emmanuele A.
    Tombolini, Vincenzo
    ANTICANCER RESEARCH, 2010, 30 (04) : 1406 - 1407
12345